Last reviewed · How we verify
Adjuvant Androgen-Deprivation Therapy
Adjuvant Androgen-Deprivation Therapy is a Androgen-deprivation therapy (combination of GnRH agonist/antagonist and/or antiandrogen) Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 3 development for Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation). Also known as: Adjuvant hormone therapy.
Adjuvant androgen-deprivation therapy suppresses testosterone production to inhibit the growth of hormone-sensitive prostate cancer cells after primary treatment.
Adjuvant androgen-deprivation therapy suppresses testosterone production to inhibit the growth of hormone-sensitive prostate cancer cells after primary treatment. Used for Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation).
At a glance
| Generic name | Adjuvant Androgen-Deprivation Therapy |
|---|---|
| Also known as | Adjuvant hormone therapy |
| Sponsor | National Taiwan University Hospital |
| Drug class | Androgen-deprivation therapy (combination of GnRH agonist/antagonist and/or antiandrogen) |
| Target | Androgen receptor; GnRH receptor (depending on specific agents used) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This therapeutic approach uses androgen-deprivation agents (such as GnRH agonists, GnRH antagonists, or antiandrogens) to lower circulating testosterone levels, thereby depriving prostate cancer cells of the hormonal signals required for proliferation. In the adjuvant setting, it is administered following primary treatment (surgery or radiation) to reduce the risk of recurrence and improve overall survival in patients with high-risk localized or locally advanced prostate cancer.
Approved indications
- Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation)
Common side effects
- Hot flashes
- Erectile dysfunction
- Decreased libido
- Fatigue
- Gynecomastia
- Weight gain
- Bone density loss / osteoporosis
- Cardiovascular events
Key clinical trials
- Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)
- Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (PHASE2)
- Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (NA)
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (PHASE3)
- A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. (PHASE2)
- SRAM study_Postate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant Androgen-Deprivation Therapy CI brief — competitive landscape report
- Adjuvant Androgen-Deprivation Therapy updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Adjuvant Androgen-Deprivation Therapy
What is Adjuvant Androgen-Deprivation Therapy?
How does Adjuvant Androgen-Deprivation Therapy work?
What is Adjuvant Androgen-Deprivation Therapy used for?
Who makes Adjuvant Androgen-Deprivation Therapy?
Is Adjuvant Androgen-Deprivation Therapy also known as anything else?
What drug class is Adjuvant Androgen-Deprivation Therapy in?
What development phase is Adjuvant Androgen-Deprivation Therapy in?
What are the side effects of Adjuvant Androgen-Deprivation Therapy?
What does Adjuvant Androgen-Deprivation Therapy target?
Related
- Drug class: All Androgen-deprivation therapy (combination of GnRH agonist/antagonist and/or antiandrogen) drugs
- Target: All drugs targeting Androgen receptor; GnRH receptor (depending on specific agents used)
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation)
- Also known as: Adjuvant hormone therapy
- Compare: Adjuvant Androgen-Deprivation Therapy vs similar drugs
- Pricing: Adjuvant Androgen-Deprivation Therapy cost, discount & access